Pionyr’s deal with Gilead could bring in more than $1B June 23, 2020 By Lee Landenberger No Comments Gilead Sciences Inc. has acquired a 49.9% equity interest in privately held Pionyr Immunotherapeutics Inc., which could receive up to $1.15 billion in potential future milestone payments in the deal.Read More